Video

Dr. Schmid on Activity With Neoadjuvant Pembrolizumab in TNBC

Peter Schmid, MD, PhD, discusses the benefit of pembrolizumab when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the benefit of pembrolizumab (Keytruda) when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC).

In KEYNOTE-522, the randomized, phase III trial randomized patients with either chemotherapy plus pembrolizumab or chemotherapy with placebo for 6 months before surgery. After surgery, patients were continually treated with pembrolizumab or placebo for 1 year.

The 2 endpoints of the trial were pathologic complete response (pCR) rate and event-free survival (EFS). Patients in the control arm had a pCR of 51.2% versus 64.8% in the pembrolizumab arm, with an absolute difference of 13.6% (95% CI, 5.4%-21.8%; P = .00055). This is a significant and meaningful difference, in which pCR can be seen as linked with positive long-term outcome and reduced risk of recurrence, concludes Schmid.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity